Codexis(CDXS) - 2024 Q4 - Annual Results

Exhibit 99.1 Codexis Reports Fourth Quarter and Fiscal Year 2024 Financial Results Total revenue of $59.3 million for the fiscal year ended December 31, 2024 Expect double digit growth for total revenue in 2025 2025 to demonstrate acceleration of commercial growth through double-stranded RNA ligase and GLP-grade siRNA material; expect to secure GMP scale-up partner REDWOOD CITY, Calif., February 27, 2025 — Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable the ...